Antiplatelet, anticoagulant, and profibrinolytic activities of baicalin

Archives of Pharmacal Research

Volumn 38, Issue 5, 2015, Pages 893-903

  Lee, Wonhwa ^a,b   Ku, Sae Kwang ^c   Bae, Jong Sup ^a  

^a Kyungpook National University   (South Korea)

^b Kyungpook National University School of Medicine   (South Korea)

^c Daegu Haany University   (South Korea)

Author keywords

Anticoagulant; Baicalin; Fibrinolysis; Platelet

Indexed keywords

ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; BAICALIN; FIBRINOLYTIC AGENT; FLAVONOID;

ANIMAL; BLOOD CLOTTING; CHEMISTRY; DOSE RESPONSE; DRUG EFFECTS; HUMAN; INSTITUTE FOR CANCER RESEARCH MOUSE; MALE; MOUSE; PHYSIOLOGY; SCUTELLARIA BAICALENSIS; UMBILICAL VEIN ENDOTHELIAL CELL;

ANIMALS; ANTICOAGULANTS; BLOOD COAGULATION; DOSE-RESPONSE RELATIONSHIP, DRUG; FIBRINOLYTIC AGENTS; FLAVONOIDS; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; MALE; MICE; MICE, INBRED ICR; PLATELET AGGREGATION INHIBITORS; SCUTELLARIA BAICALENSIS;

EID: 84939266556     PISSN: 02536269     EISSN: 19763786     Source Type: Journal    
DOI: 10.1007/s12272-014-0410-9     Document Type: Article

References (54)

1. Berk, B.C., J.I. Abe, W. Min, J. Surapisitchat, and C. Yan. 2001. Endothelial atheroprotective and anti-inflammatory mechanisms. Annals of the New York Academy of Sciences 947, 93-109. discussion 109-11.
2. Boullin, D.J., A.R. Green, and K.S. Price. 1972. The mechanism of adenosine diphosphate induced platelet aggregation: binding to platelet receptors and inhibition of binding and aggregation by prostaglandin E 1. Journal of Physiology 221: 415-426.
3. Chen, Y.C., S.C. Shen, L.G. Chen, T.J. Lee, and L.L. Yang. 2001. Wogonin, baicalin, and baicalein inhibition of inducible nitric oxide synthase and cyclooxygenase-2 gene expressions induced by nitric oxide synthase inhibitors and lipopolysaccharide. Biochemical Pharmacology 61: 1417-1427.
4. Chiu, J.H., I.S. Lay, M.Y. Su, H.L. Chiu, A.C. Chiu, W.Y. Lui, and C.W. Wu. 2002. Tumor necrosis factor-producing activity of wogonin in RAW 264.7 murine macrophage cell line. Planta Medica 68: 1036-1039.
5. Dahlback, B. 2000. Blood coagulation. Lancet 355: 1627-1632.
6. Davie, E.W. 1995. Biochemical and molecular aspects of the coagulation cascade. Thrombosis and Haemostasis 74: 1-6.
7. Davie, E.W., K. Fujikawa, and W. Kisiel. 1991. The coagulation cascade: initiation, maintenance, and regulation. Biochemistry 30: 10363-10370.
8. Day, S.M., J.L. Reeve, D.D. Myers, and W.P. Fay. 2004. Murine thrombosis models. Thrombosis and Haemostasis 92: 486-494.
9. Dejana, E., A. Callioni, A. Quintana, and G. De Gaetano. 1979. Bleeding time in laboratory animals. II - A comparison of different assay conditions in rats. Thrombosis Research 15: 191-197.
10. Despotis, G.J., G. Gravlee, K. Filos, and J. Levy. 1999. Anticoagulation monitoring during cardiac surgery: a review of current and emerging techniques. Anesthesiology 91: 1122-1151.
11. Esmon, C.T. 2005. The interactions between inflammation and coagulation. British Journal of Haematology 131: 417-430.
12. Esmon, C.T., K. Fukudome, T. Mather, W. Bode, L.M. Regan, D.J. Stearns-Kurosawa, and S. Kurosawa. 1999. Inflammation, sepsis, and coagulation. Haematologica 84: 254-259.
13. Fareed, J., I. Thethi, and D. Hoppensteadt. 2012. Old versus new oral anticoagulants: focus on pharmacology. Annual Review of Pharmacology and Toxicology 52: 79-99.
14. Fares, A. 2013. Winter cardiovascular diseases phenomenon. N Am J Med Sci 5: 266-279.
15. Fischer, K.G. 2007. Essentials of anticoagulation in hemodialysis. Hemodial Int 11: 178-189.
16. Ghosh, S., M. Ezban, E. Persson, U. Pendurthi, U. Hedner, and L.V. Rao. 2007. Activity and regulation of factor VIIa analogs with increased potency at the endothelial cell surface. Journal of Thrombosis and Haemostasis 5: 336-346.
17. Goto, S., N. Tamura, and H. Ishida. 2004. Ability of anti-glycoprotein IIb/IIIa agents to dissolve platelet thrombi formed on a collagen surface under blood flow conditions. Journal of the American College of Cardiology 44: 316-323.
18. Hamaguchi, E., T. Takamura, A. Shimizu, and Y. Nagai. 2003. Tumor necrosis factor-alpha and troglitazone regulate plasminogen activator inhibitor type 1 production through extracellular signal-regulated kinase- and nuclear factor-kappaB-dependent pathways in cultured human umbilical vein endothelial cells. Journal of Pharmacology and Experimental Therapeutics 307: 987-994.
19. Harbrecht, U. 2011. Old and new anticoagulants. Hamostaseologie 31: 21-27.
20. Hirano, T., S. Higa, J. Arimitsu, T. Naka, A. Ogata, Y. Shima, M. Fujimoto, T. Yamadori, T. Ohkawara, Y. Kuwabara, M. Kawai, H. Matsuda, M. Yoshikawa, N. Maezaki, T. Tanaka, and I. Kawase. 2006. Luteolin, a flavonoid, inhibits AP-1 activation by basophils. Biochem Biophys Res Commun 340: 1-7.
21. Izuhara, Y., S. Takahashi, M. Nangaku, S. Takizawa, H. Ishida, K. Kurokawa, C. Van Ypersele De Strihou, N. Hirayama, and T. Miyata. 2008. Inhibition of plasminogen activator inhibitor-1: its mechanism and effectiveness on coagulation and fibrosis. Arteriosclerosis, Thrombosis, and Vascular Biology 28, 672-677.
22. Jauch, E.C., J.L. Saver, H.P. Adams Jr, A. Bruno, J.J. Connors, B.M. Demaerschalk, P. Khatri, P.W. Mcmullan Jr, A.I. Qureshi, K. Rosenfield, P.A. Scott, D.R. Summers, D.Z. Wang, M. Wintermark, and H. Yonas. 2013. Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 44: 870-947.
23. Kaiser, L., and H.V. Sparks Jr. 1987. Endothelial cells. Not just a cellophane wrapper. Archives of Internal Medicine 147: 569-573.
24. Kim, D.C., S.K. Ku, and J.S. Bae. 2012a. Anticoagulant activities of curcumin and its derivative. BMB Rep 45: 221-226.
25. Kim, D.S., E.J. Son, M. Kim, Y.M. Heo, J.B. Nam, J.Y. Ro, and S.S. Woo. 2010. Antiallergic herbal composition from Scutellaria baicalensis and Phyllostachys edulis. Planta Medica 76: 678-682.
26. Kim, S.Y., S. Kim, J.M. Kim, E.H. Jho, S. Park, D. Oh, and H.S. Yun-Choi. 2011. PKC inhibitors RO 31-8220 and Go 6983 enhance epinephrine-induced platelet aggregation in catecholamine hypo-responsive platelets by enhancing Akt phosphorylation. BMB Rep 44: 140-145.
27. Kim, T.H., S.K. Ku, and J.S. Bae. 2012b. Antithrombotic and profibrinolytic activities of eckol and dieckol. Journal of Cellular Biochemistry 113: 2877-2883.
28. Ku, S.K., I.C. Lee, and JS. Bae. 2013. Antithrombotic activities of oroxylin A in vitro and in vivo. Archives of Pharmacal Research 33(5):787-792.
29. Kubo, M., H. Matsuda, M. Tanaka, Y. Kimura, H. Okuda, M. Higashino, T. Tani, K. Namba, and S. Arichi. 1984. Studies on Scutellariae radix. VII. Anti-arthritic and anti-inflammatory actions of methanolic extract and flavonoid components from Scutellariae radix. Chem Pharm Bull (Tokyo) 32: 2724-2729.
30. Lee, K.H. 2000. Research and future trends in the pharmaceutical development of medicinal herbs from Chinese medicine. Public Health Nutr 3: 515-522.
31. Lee, W., S.K. Ku, and J.S. Bae. 2013. Emodin-6-O-beta-D-glucoside down-regulates endothelial protein C receptor shedding. Arch Pharm Res 36: 1160-1165.
32. Lee, W., E.J. Yang, S.K. Ku, K.S. Song, and J.S. Bae. 2012. Anticoagulant activities of oleanolic acid via inhibition of tissue factor expressions. BMB Rep 45: 390-395.
33. Li, B.Q., T. Fu, W.H. Gong, N. Dunlop, H. Kung, Y. Yan, J. Kang, and J.M. Wang. 2000. The flavonoid baicalin exhibits anti-inflammatory activity by binding to chemokines. Immunopharmacology 49: 295-306.
34. Li, Y., Z.J. Qian, B. Ryu, S.H. Lee, M.M. Kim, and S.K. Kim. 2009. Chemical components and its antioxidant properties in vitro: an edible marine brown alga. Ecklonia cava. Bioorg Med Chem 17: 1963-1973.
35. Liu, W., M. Kato, A.A. Akhand, A. Hayakawa, M. Takemura, S. Yoshida, H. Suzuki, and I. Nakashima. 1998. The herbal medicine sho-saiko-to inhibits the growth of malignant melanoma cells by upregulating Fas-mediated apoptosis and arresting cell cycle through downregulation of cyclin dependent kinases. International Journal of Oncology 12: 1321-1326.
36. Lopez, S., F. Peiretti, B. Bonardo, I. Juhan-Vague, and G. Nalbone. 2000. Effect of atorvastatin and fluvastatin on the expression of plasminogen activator inhibitor type-1 in cultured human endothelial cells. Atherosclerosis 152: 359-366.
37. Mann, K.G., K. Brummel, and S. Butenas. 2003. What is all that thrombin for? Journal of Thrombosis and Haemostasis 1: 1504-1514.
38. Middleton Jr, E., and G. Drzewiecki. 1984. Flavonoid inhibition of human basophil histamine release stimulated by various agents. Biochemical Pharmacology 33: 3333-3338.
39. Monroe, D.M., M. Hoffman, and H.R. Roberts. 2002. Platelets and thrombin generation. Arteriosclerosis, Thrombosis, and Vascular Biology 22: 1381-1389.
40. Mukaida, N. 2000. Interleukin-8: an expanding universe beyond neutrophil chemotaxis and activation. International Journal of Hematology 72: 391-398.
41. Nowak, P., H.M. Zbikowska, M. Ponczek, J. Kolodziejczyk, and B. Wachowicz. 2007. Different vulnerability of fibrinogen subunits to oxidative/nitrative modifications induced by peroxynitrite: functional consequences. Thrombosis Research 121: 163-174.
42. Philip-Joet, F., M.C. Alessi, C. Philip-Joet, M. Aillaud, J.R. Barriere, A. Arnaud, and I. Juhan-Vague. 1995. Fibrinolytic and inflammatory processes in pleural effusions. European Respiratory Journal 8: 1352-1356.
43. Popa, C., M.G. Netea, P.L. Van Riel, J.W. Van Der Meer, and A.F. Stalenhoef. 2007. The role of TNF-alpha in chronic inflammatory conditions, intermediary metabolism, and cardiovascular risk. Journal of Lipid Research 48: 751-762.
44. Quinn, C., J. Hill, and H. Hassouna. 2000. A guide for diagnosis of patients with arterial and venous thrombosis. Clin Lab Sci 13: 229-238.
45. Rao, L.V., S.I. Rapaport, and M. Lorenzi. 1988. Enhancement by human umbilical vein endothelial cells of factor Xa-catalyzed activation of factor VII. Blood 71: 791-796.
46. Ross, R. 1999. Atherosclerosis-an inflammatory disease. New England Journal of Medicine 340: 115-126.
47. Sachs, U.J., and B. Nieswandt. 2007. In vivo thrombus formation in murine models. Circulation Research 100: 979-991.
48. Schleef, R.R., M.P. Bevilacqua, M. Sawdey, M.A. Gimbrone Jr, and D.J. Loskutoff. 1988. Cytokine activation of vascular endothelium. Effects on tissue-type plasminogen activator and type 1 plasminogen activator inhibitor. Journal of Biological Chemistry 263: 5797-5803.
49. Schouten, M., W.J. Wiersinga, M. Levi, and T. Van Der Poll. 2008. Inflammation, endothelium, and coagulation in sepsis. Journal of Leukocyte Biology 83: 536-545.
50. Sugo, T., C. Nakamikawa, S. Tanabe, and M. Matsuda. 1995. Activation of prothrombin by factor Xa bound to the membrane surface of human umbilical vein endothelial cells: its catalytic efficiency is similar to that of prothrombinase complex on platelets. Journal of Biochemistry 117: 244-250.
51. Sun, J., L. Li, J. Wu, B. Liu, W. Gong, Y. Lv, Q. Luo, X. Duan, and J. Dong. 2013. Effects of baicalin on airway remodeling in asthmatic mice. Planta Medica 79: 199-206.
52. Van Den Berg, E.A., E.D. Sprengers, M. Jaye, W. Burgess, T. Maciag, and V.W. Van Hinsbergh. 1988. Regulation of plasminogen activator inhibitor-1 mRNA in human endothelial cells. Thrombosis and Haemostasis 60: 63-67.
53. Van Hinsbergh, V.W., T. Kooistra, E.A. Van Den Berg, H.M. Princen, W. Fiers, and J.J. Emeis. 1988. Tumor necrosis factor increases the production of plasminogen activator inhibitor in human endothelial cells in vitro and in rats in vivo. Blood 72: 1467-1473.
54. Westrick, R.J., M.E. Winn, and D.T. Eitzman. 2007. Murine models of vascular thrombosis (Eitzman series). Arteriosclerosis, Thrombosis, and Vascular Biology 27: 2079-2093.